November 02, 2021
Marche-en-Famenne, Belgium
Bioxodes appoints Dr. Hans Warrinnier as Chief Medical Officer
To offer you a better experience, our website uses some cookies. To continue the visit, please accept our cookie policy
I agreeCookies information
Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:
These settings will be kept for 24h
November 02, 2021
Marche-en-Famenne, Belgium
Bioxodes appoints Dr. Hans Warrinnier as Chief Medical Officer
April 29, 2021
Marche-en-Famenne, Belgium
Bioxodes announces the completion of the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI
October 15, 2019
Marche-en-Famenne, Belgium
Bioxodes obtains authorization to launch Phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers
June 01, 2019
Marche-en-Famenne, Belgium
Bioxodes raises EUR 7.65 million to cover its clinical Phase I study and to obtain first proofs of efficacy in patients
June 01, 2015
Marche-en-Famenne, Belgium
Bioxodes raises EUR 7.9 million to bring Ir-CPI to the clinic
January 01, 2015
Marche-en-Famenne, Belgium
Bioxodes’ antithrombotic meets development milestones – Company to launch Series A financing round to bring product to the clinic
November 01, 2013
Marche-en-Famenne, Belgium
Bioxodes raises EUR 2.6 million to develop antithrombotic peptide derived from tick saliva